Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Oct 03, 2022 7:18pm
182 Views
Post# 35002825

RE:RE:RE:RE:Trogarzo 30 sec i.v. push over two weeks

RE:RE:RE:RE:Trogarzo 30 sec i.v. push over two weeksI have IM injections every 28 days and it's in the buttock. I cannot do it myself and would not want to. When Sandostatin was sill not generic, I had a nurse coming home to do it, now that it is generic, I need to go to the clinic. I don't fear it, relatively low pain, but I would not want to do it myself. And in the case of Sandostatin it is tricky because the formulation is a suspension (not a clear solution). It can block the needle easily if you don't do it quickly with the proper technique.

SPCEO1 wrote: There are other competitors either already in the space or soon to be - GILD has a pill a well. While there will always be some who would opt for a longer term solution like an injection over daily pills, I doubt there are many. Especially when the injection cannot be self-administered like Trogarzo. So, maybe IM will help more than IV Push when it is available as I am assuming it can be self-administered but I am not sure of that.

jfm1330 wrote: I disagree, for patients that does not fear needles I would take an injection every two weeks over pills.


SPCEO1 wrote: It at least gives them an excuse to get in front of more key clinic people to explain the benefits of Trogarzo IV Pushand bring up Egrifta as well. When Trogarzo's IV version was first approved, Egrifta sales really benefited from the greater access the reps had to the doctors for a while. I would not expect a giant sales jump from Trogarzo as Fostemsavir is a pill, which is still better than a 30 second needle. 

Joemare wrote: At least, this news will make the reps happy and further motivated as they got rid of a strong push-back.  The ball is in their court.

 

 

 




<< Previous
Bullboard Posts
Next >>